RxDoctor Payments DataLook up a doctor →

Rachel Crowley, PA

Medical · Paducah, KYNPI 1487801114

Payments from drug & device makers

$8,492in general payments, 2019–2025

Across 567 payments — averaging $14.98 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$2K
  • Novo Nordisk$939
  • Amgen$586
  • Eisai Inc.$480
  • Lilly USA, LLC$452
  • Boehringer Ingelheim$451
  • plus $4K from 44 others

What the payments were for

  • Food & beverage$8,492100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$8,492 in reported general payments places this provider in the 95th percentile of 222 medical providers in Kentucky.

See all medical providers in Kentucky

Medicare billing

Part B allowed, 2024
$119,190
Medicare patients
312
Services billed
2,585

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MounjaroTirzepatide84$108,516
OzempicSemaglutide78$77,418
JardianceEmpagliflozin88$69,229
EliquisApixaban49$48,139
FarxigaDapagliflozin Propanediol43$36,509
XareltoRivaroxaban30$29,401
Repatha SureclickEvolocumab39$27,603
RybelsusSemaglutide24$26,517
EntrestoSacubitril/Valsartan22$24,379
Trelegy ElliptaFluticasone/Umeclidin/Vilanter18$17,961
JanuviaSitagliptin Phosphate25$17,703
LinzessLinaclotide20$13,139
TrulicityDulaglutide12$13,127
QuliptaAtogepant12$12,900
Repatha SyringeEvolocumab15$12,721

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCMounjaro, Trulicity$452$121,64296 claims
Novo NordiskOzempic, Rybelsus$939$103,936102 claims
Boehringer IngelheimJardiance$451$69,22988 claims
PfizerEliquis$260$48,13949 claims
AstraZenecaFarxiga$437$36,50943 claims
Johnson & JohnsonXarelto$216$29,40130 claims
AbbVieLinzess, Qulipta, Synthroid$1,643$26,90345 claims
NovartisEntresto$445$24,37922 claims
GSKTrelegy Ellipta$43$17,96118 claims
MerckJanuvia$114$17,70325 claims
Astellas Pharma US IncMyrbetriq$163$8,56617 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 222 medical providers in Kentucky.

Other medical in Paducah

See the full list for Kentucky

Where these figures come from

Is this you, or does something look wrong? →